ClinicalTrials.gg
TerminatedNCT05814536Updated Oct 18, 2024

IDH1 Inhibitor AB-218 in Patients With Advanced IDH1 Mutant Cholangiocarcinoma and Other Solid Tumor

A Phase 1 interventional study of AB-218 capsule in Cholangiocarcinoma With IDH1 Mutation and Solid Tumors With IDH1 Mutation, sponsored by AnHeart Therapeutics Inc.. Terminated at 14 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-18.

Sponsored by AnHeart Therapeutics Inc. (part of Nuvation Bio Inc.) · Phase 1, Interventional, and Treatment

Why this study was terminated
Sponsor adjusted the study strategy

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 230 studies in Cholangiocarcinoma with a site in China — 114 open to participants now, 124 under way, 12 of them phase 3. Cholangiocarcinoma · China.

Enrollment
184th of 191
9 · median 51
Started
2023
with 24 others
Phase 1
19 of 230
10 open now
Registered
124th of 230
by date

Among the 230 studies in Cholangiocarcinoma with a site in China, this one is the 184th largest by enrollment of the 191 interventional ones that give a count, is one of 25 that started in 2023, is one of 19 in phase 1, and was the 124th registered.

Cholangiocarcinoma

825 studies on the registry are indexed under Cholangiocarcinoma; 288 are open to participants now.

Browse Cholangiocarcinoma studies →

Open to participants now

114 of the 230 studies in Cholangiocarcinoma with a site in China are open now. Recruiting first, the newest first:

109 more — sign in →

All 114 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 211 Cholangiocarcinoma studies recruiting now, 141 (67%) set no upper age limit and 49 (23%) stop at 75 or younger; 10 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 230 studies in Cholangiocarcinoma with a site in China, or all of them as a file.
02

Study summary

This is an open label, single-arm Phase I study to evaluate the safety, tolerability, PK and preliminary efficacy of AB-218, an oral IDH1 inhibitor, for the treatment of adult patients with advanced IDH1 mutant cholangiocarcinoma and other solid tumors who have failed at least one prior therapy in the advanced stage.

The study contains a dose escalation part and a dose expansion part. In the dose escalation part, participants are enrolled sequentially into one of 3 dose levels of AB-218 (125 mg BID, 250 mg BID and 500 mg BID) following a 3+3 rule. Intensive PK sampling will be performed during the dose escalation part. Participants will be followed up for DLTs from the date of first study dose to 28 days afterwards. When all participants in the dose escalation part have completed the 28-day DLT observation period, SMC will review the available data including but not limited to safety, tolerability and PK, and then recommend the dose for the study dose expansion part.

In the dose expansion part, there are 2 disease cohorts planned: cholangiocarcinoma (CCA) and other IDH1 mutant solid tumors. It is planned to enrol 30 participants in the CCA cohort and another 15 participants in other IDH1 mutant solid tumors, to assess the safety and preliminary efficacy of AB-218. Sparse PK samples will be collected to further evaluate the PK profile in the different target populations.

Each participant will undergo screening up to 28 days prior to the start of the treatment period. The treatment period consists of a visit on Day 1 of every 28-day cycle and continues until any of disease progression, unacceptable toxicity, withdrawal of consent or death. An end of treatment (or early discontinuation) visit occurs 30 days (± 7 days) after the last dose of study medication, and a survival follow call every 12 weeks until death, withdrawal of informed consent, loss to follow-up (LTFU) or termination of the study by the sponsor, whichever occurs first.

03

Conditions studied

  • Cholangiocarcinoma With IDH1 Mutation
  • Solid Tumors With IDH1 Mutation

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must be ≥18 years of age at the time of signing the form.
  2. Must have locally advanced or solid tumors that have recurred or progressed following treatment with at least 1 prior systemic therapy, or that have not responded to prior systemic therapy; or the patient is unfit for any intensive chemotherapy in the setting.
  3. Must have confirmed IDH1 mutation from testing of a primary or metastatic tumor before first study treatment. Patients must have archival primary tumor or surgical specimens, or biopsies of recurrence of metastasis for IDH1 mutation confirmation and status of other concurrent gene mutations. Patients shall provide formalin-fixed paraffin-embedded (FFPE) tissue slides without staining, which are shipped to the designated laboratory. The IDH1 mutation must be determined by a validated assay as performed in Clinical Laboratory Improvement Amendments (CLIA)-certified/College of American Pathologists (CAP)-accredited or locally equivalent clinical laboratories. Patients whose tumors have not been tested for IDH1 mutation, must be consented with the pre-screening ICF to allow collection of tumor tissue and testing at the designated qualified central laboratory. These patients may only be consented to the study with the full ICF if they have a documented IDH1 mutation.
  4. Must have a (s) as per the v1.1 criteria.
  5. Patients with chronic infection are acceptable to enroll, if ≥ 4 weeks between achieving sustained viral response and start of study drug. Anti-viral therapy is allowed during the study treatment period.
  6. Patients with chronic infection may enroll in the study, if HBV DNA is \<1000 copies/mL prior to the start of study treatment. Anti-viral therapy is allowed during the study treatment period.
  7. Must have ≥ 3 months.
  8. Must have (ECOG) performance status (PS) score ≤ 1.
  9. Must have a class A liver score within 7 days prior to first dose of study treatment.
  10. Must have adequate organ functions as defined below:

    (ANC)≥ 1.5 X 109/L, ≥ 80 g/L * (Cockcroft-Gault Formula) ≥ 60 mL/min Total ≤ 2 x ,≤ 3 x ULN, for participants with documented Gilbert's syndrome and ALT≤ 5 x ULN, Albumin≥ 30 g/L, ≤ 1.5 x ULN unless patient is receiving anti-coagulant therapy, aPTT must be within the therapeutic range of intended use of anticoagulants

  11. Adequate biliary drainage, with no evidence of ongoing infection (patients on maintenance antibiotics are eligible when acute sepsis has resolved)
  12. Recovery to Grade 1 from any toxicities due to prior therapies, except conditions such as peripheral neuropathy, alopecia and irreversible changes associated with radiation therapy; peripheral neuropathy due to prior therapies must have recovered to ≤ Grade 2.
  13. Female patients who engage in heterosexual intercourse must be of nonchildbearing potential, defined as either surgically sterile (i.e., hysterectomy, bilateral salpingectomy, or bilateral oophorectomy), OR be with at least 1 year of amenorrhea, OR must agree to use a highly effective method of from the beginning of Screening until at least 90 days after the last dose of study drug.

    • Acceptable highly effective methods of contraception include:
    • Combined estrogen-progestin oral hormonal contraception associated with consistent inhibition of ovulation.
    • Desogestrel based progestin only contraception associated with consistent inhibition of ovulation; this includes oral, injectable, and implantable methods
    • Intravaginal and transdermal hormone delivery methods
    • Intrauterine device (with or without hormone elution)
    • Bilateral tubal occlusion or ligation (must be documented)
    • Vasectomized partner (must be documented) or
    • Sexual abstinence (only when it is the usual and preferred lifestyle of the patient)
  14. Male patients must agree to use a condom when sexually active with a female partner of from Screening until at least 90 days after the last dose of study drug (or be surgically sterile [i.e., vasectomy with documentation]; or remain abstinent [when this is in line with the preferred and usual lifestyle]. Male patients should also agree not to donate sperm for the duration of the study and until at least 90 days after the last dose of study drug.
  15. Must be capable of giving signed informed consent as described in Appendix 1 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  16. Must be able to undergo the protocol-specified procedures, including blood tests, urinalysis.

Exclusion criteria

Exclusion Criteria:

  1. Patients diagnosed with IDH1 mutant glioma or acute myeloid leukemia (AML).
  2. Patients with history or complication of any of the following diseases within 3 months prior to the initial dose of the drug.

    • Myocardial infarction
    • Severe or unstable angina pectoris
    • Coronary or peripheral endovascular treatment
    • Heart failure
    • Cerebrovascular disorder including , stroke, central nervous system (CNS) bleeding.
  3. Uncontrolled active systemic fungal, bacterial, or other infection (despite appropriate antibiotics or other treatment).
  4. infection as determined by an HIV antibody test.
  5. Presence of Grade 3 ascites, as defined in the Guidance on the Management of Ascites and Complications in Cirrhosis 36. The patient has significant bloating, tests positive for shifting dullness, and may have abdominal distension leading to umbilical hernia; on assessment with ultrasound, the ascites occupies the entire abdominal cavity, and the middle abdomen is filled with ascites, with a depth of >10 cm.
  6. Gastrointestinal diseases that may interfere with oral ingestion of the study drug or may affect absorption of the study drug.
  7. Prior anticancer therapy, within the applicable periods shown below, before the start of the protocol treatment:

    • Systematic Therapy: within 3 weeks
    • Radical Surgery: within 3 weeks
    • Radiation therapy: within 12 weeks (excluding the palliative radiotherapy or radiotherapy on the non-target lesions)
    • Infusion of blood component or the recombinant human blood product, for example, RBC, , rhGSF: within 2 weeks
  8. Have received prior anti-cancer therapy targeted to the IDH1 mutation.
  9. Patients taking substrates of cytochrome CYP2C8, CYP2C9, and with narrow therapeutic window, should be excluded unless they can be transferred to other medications prior to enrolling. Patients taking sensitive CYP 2C8, 2C9 or 3A4 substrate medications may require dosage adjustment unless they can be transferred to other medications within ≥ 5 half-lives prior to dosing.
  10. Patients taking sensitive substrates of P-gp and BCRP transporters should be excluded unless they can be transferred to other medications prior to enrolling. Patients taking sensitive substrates of P-gp and BCRP may require dosage adjustment unless they can be transferred to other medications within ≥ 5 half-lives prior to dosing.
  11. Known to the investigational medicinal product or to any drug with similar chemical structure or to any other present in the pharmaceutical form of the investigational medicinal product(s).
  12. Advanced arrhythmia of Grade ≥ 2 per (CTCAE) v5.0, uncontrolled atrial fibrillation (any grade) and >470 msec for females or >450 msec for males.
  13. Pregnant or breastfeeding female patient.
  14. Psychiatric disease or symptoms that may interfere with continuous participation in the study.
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    AB-218

    AB-218 for the treatment of adult patients with advanced cholangiocarcinoma, chondrosarcoma and other solid tumors with IDH1 mutation.

    Drug: AB-218 capsule

Interventions

  • Take AB-218 orally twice daily, ideally with 12 hours between doses (and a minimum of 8 hours between doses), at a dose assigned by the study. The study treatment is defined as occurring in 28-day cycles with continuous dosing. Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs earlier.

06

What researchers measure

Primary outcomes

  1. TEAEs

    Treatment-Emergent Adverse Events (TEAEs) including events reported following physical examination, vital signs assessment, clinical laboratory assessment or electrocardiogram (ECG)

    Time frame: About 24 months

  2. DLT incidence

    Dose limiting toxicity incidence

    Time frame: Dose escalation part, about 6 months

Secondary outcomes

  1. Overall Response Rate

    Proportion of subjects with the best overall confirmed response of complete response (CR) or partial response (PR) according to RECIST v1.1

    Time frame: About 24 months

  2. Duration of Response

    Defined as the time from the first date of objective response (CR or PR) to the first documented date of disease progression. Response assessments are per RECIST v1.1 criteria and are investigator designated

    Time frame: About 24 months

  3. Disease Control Rate

    Defined as the proportion of subjects with a best overall response of CR, PR or stable disease per RECIST v1.1 criteria) as assessed by the investigator

    Time frame: About 24 months

  4. Progress Free Survival

    Defined as the time from first dose of AB 218 until the date of disease progression, or death from any cause. Response assessments are per RECIST v1.1 criteria and are investigator designated.

    Time frame: About 24 months

  5. Overall Survival

    Defined as the time from the first dose of AB 218 to death due to any cause.

    Time frame: About 48 months

  6. Cmax

    Plasma drug peak concentration

    Time frame: 8 Days. At the Day1 and Day8 of Cycle1 for dose escalation part and dose expansion part(each cycle is 28 days)

  7. Tmax

    Time to reach plasma drug peak concentration

    Time frame: 8 Days. At the Day1 and Day8 of Cycle1 for dose escalation part and dose expansion part(each cycle is 28 days)

  8. AUC8h

    Area under the plasma drug concentration time curve from 0 to 8h

    Time frame: 8 Days. At the Day1 and Day8 of Cycle1 for dose escalation part(each cycle is 28 days)

  9. AUC12h

    Area under the plasma drug concentration time curve from 0 to 12h

    Time frame: 8 Days. At the Day1 and Day8 of Cycle1 for dose escalation part(each cycle is 28 days)

  10. AUC6h

    Area under the plasma drug concentration time curve from 0 to 6h

    Time frame: 8 Days. At the Day1 and Day8 of Cycle1 for dose expansion part(each cycle is 28 days)

  11. Ctrough

    Trough concentration

    Time frame: 4 Months. At the end of Cycle 4 (each cycle is 28 days).

  12. Plasma concentration of 2-HG

    Plasma concentration of 2-HG

    Time frame: 4 Months. At the end of Cycle 4 (each cycle is 28 days).

07

Study locations

14 sites
  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
    Beijing, Beijing 100730, China
  • Beijing Jishuitan Hospital
    Beijing, Beijing, China
  • Mengchao Hepatobiliary Hospital of Fujian Medical University
    Fuzhou, Fujian, China
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong, China
  • The First Affiliated Hospital of Sun Yat-sen University
    Guangzhou, Guangdong, China
  • The fourth hospital of Hebei medical university
    Shijiazhuang, Hebei, China
  • Henan Cancer Hospital
    Zhengzhou, Henan, China
  • Liaoning Cancer Hospital
    Shenyang, Liaoning, China
  • Shandong Cancer Hospital
    Jinan, Shandong, China
  • Affiliated Hospital of Qingdao University
    Qingdao, Shandong, China
  • Shanghai Sixth People's Hospital
    Shanghai, Shanghai, China
  • The Third Affiliated Hospital of the PLA naval medical university
    Shanghai, Shanghai, China
  • Shulan (Hangzhou) Hospital
    Hangzhou, Zhejiang, China
  • Jinan Central Hospital
    Jinan, Zhejiang, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2023 to primary completion in Aug 2024, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2023
First posted
Apr 18, 2023
StartActual
May 6, 2023
Primary completionActual
Aug 15, 2024
CompletionActual
Aug 15, 2024
Last update
Oct 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05814536
Responsible party
Sponsor
First posted
Apr 18, 2023
Start date
May 6, 2023
Primary completion
Aug 15, 2024
Completion
Aug 15, 2024
Last update
Oct 18, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Safusidenib

Start the discussion